OBJECTIVES:: To identify the main cost drivers associated with Idiopathic Pulmonary Fibrosis-IPF in the international context to make evident the healthcare attention challenges in Colombia. METHODS:: The comprehensive review of the literature in the following databases: Medline, Embase, Econlit and Health Technology Assessment Database and, the search of “grey” literature published between January 1990 and February 2017, was conducted. The inclusion criteria were: IPF and its association with comorbidities, use of healthcare services and direct costs from the third payer perspective. A statistical analysis was performed using measures of central tendency. Finally, the identified evidence was used as reference to make recommendations regarding the management of IPF in Colombia. RESULTS:: Nine articles in indexed journals and 8 posters in specialized medical congresses were identified. The evidence included population registers up to 2011. The median of the main comorbidities was: 30.6% for pulmonary infections, 32% for coronary diseases and 25.3% for cardiovascular problems. Functional deterioration and loss on quality of life resulted in a high use of healthcare services such as referrals to specialists, emergency consultations and hospitalization. The median annual cost for patient was US $ 58,164 associated with assisted ventilation, hospitalizations, and emergency room visits. CONCLUSIONS::  Nine articles in indexed journals and 8 posters in specialized medical congresses were identified. The evidence included population registers up to 2011. The median of the main comorbidities was: 30.6% for pulmonary infections, 32% for coronary diseases and 25.3% for cardiovascular problems. Functional deterioration and loss on quality of life resulted in a high use of healthcare services such as referrals to specialists, emergency consultations and hospitalization. The median annual cost for patient was US $ 58,164 associated with assisted ventilation, hospitalizations, and emergency room visits.